Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1997 6
1998 2
1999 1
2000 2
2001 3
2002 7
2003 3
2004 4
2005 6
2006 5
2007 8
2008 10
2009 10
2010 11
2011 19
2012 14
2013 21
2014 17
2015 18
2016 22
2017 21
2018 25
2019 26
2020 39
2021 45
2022 37
2023 44
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

394 results

Results by year

Filters applied: . Clear all
Page 1
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, Dücker P, Ertl C, Tomsitz D, Tietze JK, Gutzmer R, Dabrowski E, Zimmer L, Gesierich A, Zierold S, French LE, Eigentler T, Amaral T, Heinzerling L. Ruf T, et al. Among authors: gutzmer r. Eur J Cancer. 2024 Mar 27;203:114028. doi: 10.1016/j.ejca.2024.114028. Online ahead of print. Eur J Cancer. 2024. PMID: 38652976
Laudatio zum 80. Geburtstag von Prof. Dr. med. Wolfgang Tilgen.
Pföhler C, Ugurel S, Gutzmer R. Pföhler C, et al. Among authors: gutzmer r. J Dtsch Dermatol Ges. 2024 Apr;22(4):631-632. doi: 10.1111/ddg.15395_g. J Dtsch Dermatol Ges. 2024. PMID: 38574025 German. No abstract available.
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations.
Schaper-Gerhardt K, Gutzmer R, Angela Y, Zimmer L, Livingstone E, Schadendorf D, Hassel JC, Weishaupt C, Remes B, Kubat L, Spassova I, Becker JC. Schaper-Gerhardt K, et al. Among authors: gutzmer r. Eur J Cancer. 2024 May;202:113984. doi: 10.1016/j.ejca.2024.113984. Epub 2024 Mar 2. Eur J Cancer. 2024. PMID: 38479119 Free article.
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy OJ, Glassee N, Kicinski M, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Giacomo AMD, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Gandini S, Buhrer E, Suciu S, Robert C, Eggermont AMM, Mandala M, Lorigan P, Valpione S. Kennedy OJ, et al. Among authors: gutzmer r. Eur J Cancer. 2024 Apr;201:113585. doi: 10.1016/j.ejca.2024.113585. Epub 2024 Feb 1. Eur J Cancer. 2024. PMID: 38402687 Clinical Trial.
Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid.
Kramer N, Müller G, Zierold S, Röckel M, Fröhlich W, Schefzyk M, Kumbrink J, Hassel JC, Berking C, Ziemer M, Nashan D, French LE, Vera J, Kerl-French KE, Gutzmer R, Heinzerling L. Kramer N, et al. Among authors: gutzmer r. J Eur Acad Dermatol Venereol. 2024 Feb 24. doi: 10.1111/jdv.19860. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38400651 No abstract available.
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade.
Chorti E, Kowall B, Hassel JC, Schilling B, Sachse M, Gutzmer R, Loquai C, Kähler KC, Hüsing A, Gilde C, Thielmann CM, Zaremba-Montenari A, Placke JM, Gratsias E, Martaki A, Roesch A, Ugurel S, Schadendorf D, Livingstone E, Stang A, Zimmer L. Chorti E, et al. Among authors: gutzmer r. Eur J Cancer. 2024 Mar;200:113536. doi: 10.1016/j.ejca.2024.113536. Epub 2024 Jan 18. Eur J Cancer. 2024. PMID: 38306840 Free article.
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.
Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, Bergwelt-Baildon MV, Subklewe M, Tomsitz D, Ascierto PA, Dummer R, Gogas H, Lebbé C, Long GV, McArthur G, Neilan TG, Ribas A, Robert C, Schadendorf D, Zimmer L, Eigentler T, Grabbe S, Forschner A, Kähler KC, Milani V, Pföhler C, Hassel J, Gutzmer R, Loquai C, Routy B, Furness AJS, Blank C, Wolchok JD, French LE, Hauschild A, Heinzerling L. Ertl C, et al. Among authors: gutzmer r. Eur J Cancer. 2024 Mar;199:113505. doi: 10.1016/j.ejca.2023.113505. Epub 2023 Dec 23. Eur J Cancer. 2024. PMID: 38262306
Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG.
Kochanek C, Gilde C, Zimmer L, Ugurel S, Meier F, Utikal J, Pföhler C, Herbst R, Haferkamp S, Welzel J, Dücker P, Leiter U, Weichenthal M, von Wasielewski I, Angela Y, Gutzmer R. Kochanek C, et al. Among authors: gutzmer r. Eur J Cancer. 2024 Feb;198:113508. doi: 10.1016/j.ejca.2023.113508. Epub 2023 Dec 28. Eur J Cancer. 2024. PMID: 38183763 Free article.
394 results